Safety of sofosbuvir‐based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study

Abstract

The eGFR varies during treatment and gives a confusing picture of the renal safety of sofosbuvir-based regimens. In contrast, longitudinal assessment of the eGFR shows a rising trajectory over longer time, meaning that these therapies are safe for the kidneys in our cohort of liver transplant recipients.

Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct‐acting antivirals: Therapy of HCV‐recurrence

“…The number appears to be small, but the observation of a safe and effective performance of full‐dose SOF disregarding the extent of renal insufficiency must not be neglected. Treatment options of HCV‐genotype‐3‐infection in patients with impaired kidney function before and after LT are limited and may require SOF as a backbone of AVT which also could be recently demonstrated by Anty et al This observation delivers valuable information on a safe use of SOF‐based regimens. Hundemer et al made similar observations in a small cohort of patients with renal insufficiency in a non‐LT setting.…”

Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals

“…Several studies have reported that the estimated glomerular filtration rate (eGFR) might be reduced during DAA therapy, especially sofosbuvir (SOF) -based regimens [ 7 – 13 ]. However, some studies have revealed that the eGFR change might be nonsignificant [ 10 , 11 , 13 – 16 ]. The metabolite of SOF is mainly cleared from the body via the kidney, but other kinds of DAAs are primarily metabolized and cleared by the liver [ 1 ], SOF-based DAA could be nephrotoxic.…”

Untitled

“…However, the short-term effect of DAA on renal function is inconclusive [5,6]. Several studies have reported that the estimated glomerular filtration rate (eGFR) might be reduced during DAA therapy, especially sofosbuvir (SOF) -based regimens [7][8][9][10][11][12][13]. However, some studies have revealed that the eGFR change might be nonsignificant [10,11,[13][14][15][16].…”

“…Several studies have reported that the estimated glomerular filtration rate (eGFR) might be reduced during DAA therapy, especially sofosbuvir (SOF) -based regimens [7][8][9][10][11][12][13]. However, some studies have revealed that the eGFR change might be nonsignificant [10,11,[13][14][15][16]. The metabolite of SOF is mainly cleared from the body via the kidney, but other kinds of DAAs are primarily metabolized and cleared by the liver [1], SOF-based DAA could be nephrotoxic.…”